Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

DOVATO Film-coated tablet (2020)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

1. Name of the medicinal product

Dovato 50 mg/300 mg film-coated tablets.

2. Qualitative and quantitative composition

Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir and 300 mg lamivudine. For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Film-coated tablet (tablet). Oval, biconvex, white, film coated tablet, approximately 18.5 9.5 mm, debossed with SV 137 on one face.

4.1. Therapeutic indications

Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance ...

4.2. Posology and method of administration

Dovato should be prescribed by physicians experienced in the management of HIV infection. Posology Adults and adolescents (above 12 years of age weighing at least 40 kg). The recommended dose of Dovato ...

4.3. Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. Co-administration with medicinal products with narrow therapeutic windows, that are substrates of organic cation ...

4.4. Special warnings and precautions for use

Transmission of HIV While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions ...

4.5. Interaction with other medicinal products and other forms of interaction

No drug interaction studies have been conducted using Dovato. Dovato contains dolutegravir and lamivudine, therefore any interactions identified for these individually are relevant to Dovato. No clinically ...

4.6. Fertility, pregnancy and lactation

Women of childbearing potential Women of childbearing potential (WOCBP) should be counselled about the potential risk of neural tube defects with dolutegravir (a component of Dovato, see below), including ...

4.7. Effects on ability to drive and use machines

Dovato has no or negligible influence on the ability to drive and use machines. Patients should be informed that dizziness and somnolence has been reported during treatment with dolutegravir. The clinical ...

4.8. Undesirable effects

Summary of the safety profile The most frequently reported adverse reactions are headache (3%), diarrhoea (2%), nausea (2%) and insomnia (2%). The most severe adverse reaction reported with dolutegravir ...

4.9. Overdose

No specific symptoms or signs have been identified following acute overdose with dolutegravir or lamivudine, apart from those listed as adverse reactions. There is no specific treatment for an overdose ...

5.1. Pharmacodynamic properties

<b>Pharmacotherapeutic group:</b> Antivirals for systemic use, antivirals for treatment of HIV infections, combinations <b>ATC code:</b> J05AR25 Mechanism of action Dolutegravir inhibits HIV integrase ...

5.2. Pharmacokinetic properties

When administered in fasted state, bioequivalence regarding C<sub>max</sub> was achieved for dolutegravir, when comparing Dovato to dolutegravir 50 mg co-administered with lamivudine 300 mg. Dolutegravir ...

5.3. Preclinical safety data

There are no data available on the effects of the combination of dolutegravir and lamivudine in animals. Carcinogenesis and mutagenesis Dolutegravir was not mutagenic or clastogenic using in vitro tests ...

6.1. List of excipients

<u>Tablet core:</u> Microcrystalline cellulose Sodium starch glycolate Magnesium Stearate Mannitol (E421) Povidone (K29/32) Sodium stearyl fumarate <u>Tablet coating:</u> Hypromellose (E464) Macrogol ...

6.2. Incompatibilities

Not applicable.

6.3. Shelf life

2 years.

6.4. Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5. Nature and contents of container

Opaque, white HDPE (high density polyethylene) bottles closed with child resistant polypropylene closures, with a polyethylene faced induction heat seal liner. Each pack consists of one bottle containing ...

6.6. Special precautions for disposal and other handling

No special requirements for disposal.

7. Marketing authorization holder

ViiV Healthcare BV, Van Asch van Wijckstraat 55H, 3811 LP Amersfoort, Netherlands

8. Marketing authorization number(s)

EU/1/19/1370/001 EU/1/19/1370/002

9. Date of first authorization / renewal of the authorization

Date of first authorization: 1st July 2019

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: